Reduction of Pro-Inflammatory Synovial Fluid Biomarkers in Osteoarthritis of the Knee With Alpha-2 Macroglobulin
Status: | Recruiting |
---|---|
Conditions: | Arthritis, Osteoarthritis (OA) |
Therapuetic Areas: | Rheumatology |
Healthy: | No |
Age Range: | 18 - 90 |
Updated: | 10/19/2018 |
Start Date: | November 1, 2017 |
End Date: | March 12, 2019 |
Contact: | Hien Pham |
Email: | hien.pham@nyumc.org |
Phone: | (626) 807-8727 |
Reduction of Pro-Inflammatory Synovial Fluid Biomarkers in Osteoarthritis of the Knee With Alpha-2 Macroglobulin: A Randomized Controlled Trial
The purpose of the current study is to assess the ability of alpha-2-macroglobulin treatment
to reduce the level of pro-inflammatory synovial fluid biomarkers in patients with
osteoarthritis of the knee.
This is a double-blinded rationalized control trial with prospective data collection. The
study will collect and analyze the synovial fluid, serum, and urine of patients presenting
with knee osteoarthritis in Kellegren-Lawrence grade 2 or 3. It will compare synovial fluid
biomarker levels between patients receiving an intra-articular alpha-macroglobulin,
intra-articular PR injection and intra-articular corticosteroid serving as a control.
Pre-injection pain and function will be assessed. Post-injection pain, function and outcomes
will be assessed after six weeks and three months.
to reduce the level of pro-inflammatory synovial fluid biomarkers in patients with
osteoarthritis of the knee.
This is a double-blinded rationalized control trial with prospective data collection. The
study will collect and analyze the synovial fluid, serum, and urine of patients presenting
with knee osteoarthritis in Kellegren-Lawrence grade 2 or 3. It will compare synovial fluid
biomarker levels between patients receiving an intra-articular alpha-macroglobulin,
intra-articular PR injection and intra-articular corticosteroid serving as a control.
Pre-injection pain and function will be assessed. Post-injection pain, function and outcomes
will be assessed after six weeks and three months.
Inclusion Criteria:
- Patients osteoarthritis classified as Kellegren-Lawrence grade 2 or 3
Exclusion Criteria:
- Mentally impaired (e.g, Alzheimer's subjects, dementia, etc.)
- Younger than 18 years of age
- Greater than 90 years of age
- Patients with underlying inflammatory arthropathies
We found this trial at
1
site
550 1st Ave
New York, New York 10016
New York, New York 10016
(212) 263-7300
Principal Investigator: Laith Jazrawi, MD
Phone: 626-807-8727
New York University School of Medicine NYU School of Medicine has a proud history that...
Click here to add this to my saved trials